Amazon Pharmacy will begin offering Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, popular GLP-1 drugs for weight loss, to patients enrolled in Medicare Part D plans.

This move marks a significant expansion of access to these highly sought-after medications, which have seen surging demand. The drugs, known for their effectiveness in aiding weight management, will be available through Amazon's pharmacy service for a monthly cost of $50.

This offering is expected to increase competition in the weight-loss drug market and provide a new, potentially more accessible channel for Medicare beneficiaries to obtain these treatments. The partnership aims to simplify the process for eligible patients to access and manage their prescriptions.